| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3056141 | Experimental Neurology | 2010 | 8 Pages |
Abstract
The endocannabinoid system may be the target of novel therapies in a wide variety of diseases. Among them, those related with amyloid accumulation will be discussed in the present review. Several components of this system (CB1 and CB2 receptors, endocannabinoids, FAAH enzyme) may participate in different aspects of amyloid pathophysiology such as, for instance, synaptic activity, cell migration, cytokine production or phagocytic activity. Consistent with recent data, putative lines of research and hypothesis will be discussed.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Lourdes Ruiz-Valdepeñas, Cristina Benito, Rosa María Tolón, José Antonio Martínez Orgado, Julián Romero,